bNeisseria meningitidis asymptomatically colonizes the human upper respiratory tract but is also the cause of meningitis and severe septicemia. Carriage or disease evokes an immune response against the infecting strain. Hitherto, we have known little about the breadth of immunity induced by natural carriage of a single strain or its implications for subsequent infectious challenge. In this study, we establish that transgenic mice expressing human CEACAM1 support nasal colonization by a variety of strains of different capsular types. Next, we nasally challenged these mice with either of the N. meningitidis strains H44/76 (serogroup B, ST-32) and 90/18311 (serogroup C, ST-11), while following the induction of strain-specific immunoglobulin. When these antisera were tested for reactivity with a diverse panel of N. meningitidis strains, very low levels of antibody were detected against all meningococcal strains, yet a mutually exclusive "fingerprint" of high-level cross-reactivity toward certain strains became apparent. To test the efficacy of these responses for protection against subsequent challenge, CEACAM1-humanized mice exposed to strain 90/18311 were then rechallenged with different N. meningitidis strains. As expected, the mice were immune to challenge with the same strain and with a closely related ST-11 strain, 38VI, while H44/76 (ST-32) could still colonize these animals. Notably, however, despite the paucity of detectable humoral response against strain 196/87 (ST-32), this strain was unable to colonize the 90/18311-exposed mice. Combined, our data suggest that current approaches may underestimate the actual breadth of mucosal protection gained through natural exposure to N. meningitidis strains. N eisseria meningitidis is the causative agent of meningococcal meningitis and septicemia. Both manifestations of invasive meningococcal disease (IMD) primarily affect infants and toddlers and are characterized by a rapid course of progression (1). The fatality rate is particularly high in meningococcal sepsis, and treatment options are limited, especially when patients present in hospitals with late-stage disease (2). Therefore, preemptive measures such as vaccination are pivotal in the defense against this human-specific pathogen.Although mainly recognized because of its devastating invasive potential, N. meningitidis bacteria are normal inhabitants of the human upper respiratory tract, as about 10% of the general population carry these bacteria in their throats (3, 4). Overall, progression into disease is uncommon and is limited to certain hypervirulent lineages of this diverse species (5, 6). One key aspect in meningococcal virulence is the polysaccharide capsule, which shields the bacteria against the bactericidal activities of the host through phagocytosis and the complement system and which allows for their survival and multiplication in the blood. In order to overcome this protective function, immunoglobulin specific for surface antigens is required to facilitate Fc receptor-mediated phagocytosis and ser...